Is Sight Sciences Inc (SGHT) overvalued? · rev $43.1M
Sight Sciences Inc (SGHT) is a medical devices company listed on NASDAQ.
This page asks whether Sight Sciences Inc (SGHT) looks expensive on cached numbers — not a short thesis.
Latest reported SGHT revenue for 2026-06-30 was $43.1M. Net income was -$17.4M. SGHT currently screens at market cap $273.1M.
SGHT currently screens at market cap $273.1M. A high multiple can be growth prepaid or a bubble. The filing has to explain the gap.
If the next SGHT 8-K cuts growth or raises capex, this “expensive” read gets worse. Until then the SEC page is the source.
Not investment advice. Use the SGHT stock page for the full model, not this heading.
Not investment advice.